Wexford Capital LP Arcus Biosciences, Inc. Transaction History

Wexford Capital LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$28.92 - $41.83 $283,416 - $409,934	-9,800 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$31.38 - $48.47 $69,036 - $106,634	-2,200 Reduced 18.33%	9,800 $397,000
Q2 2021 Aug 16, 2021	BUY	$22.75 - $35.77 $273,000 - $429,240	12,000 New	12,000 $330,000
Q1 2021 May 13, 2021	SELL	$26.16 - $41.39 $147,804 - $233,853	-5,650 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$17.14 - $25.47 $75,416 - $112,068	4,400 Added 352.0%	5,650 $97,000
Q2 2020 Aug 13, 2020	BUY	$13.97 - $36.56 $17,462 - $45,700	1,250 New	1,250 $31,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.12B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Wexford Capital LP, based on Form 13F filings with the SEC.

Stay updated on Wexford Capital LP with notifications on news.